Get the Stockscreener App
9.98
1.73%
0.17
Elicio Therapeutics Inc stock is traded at $9.98, with a volume of 21,884.
It is up +1.73% in the last 24 hours and up +29.27% over the past month.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
See More
Previous Close:
$9.81
Open:
$9.84
24h Volume:
21,884
Relative Volume:
0.54
Market Cap:
$159.65M
Revenue:
-
Net Income/Loss:
$-33.82M
P/E Ratio:
-0.39
EPS:
-25.5891
Net Cash Flow:
$-66.04M
1W Performance:
+0.91%
1M Performance:
+29.27%
6M Performance:
+7.20%
1Y Performance:
+96.46%
1-Day Range:
$9.20
$9.99
1-Week Range:
$9.20
$10.75
52-Week Range:
$3.70
$10.75
Elicio Therapeutics Inc Stock (ELTX) Company Profile
Name
Elicio Therapeutics Inc
Sector
Industry
Phone
(857) 209-0050
Address
451 D STREET, 5TH FLOOR, BOSTON
Compare ELTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
9.98 | 156.93M | 0 | -33.82M | -66.04M | -25.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Elicio Therapeutics Inc Stock (ELTX) Latest News
Visual trend scoring systems applied to Elicio Therapeutics Inc.Risk Shielded Trade Watch with Analysis - Newser
Is Elicio Therapeutics Inc. trending in predictive chart modelsFree Swing Trading Plan With Smart Signals - Newser
Intraday pattern recognizer results for Elicio Therapeutics Inc.Swing Trade Picks with High Potential - Newser
Predicting Elicio Therapeutics Inc. trend using moving averagesFree Value Investing Picks With Stability - Newser
Can trapped investors hope for a rebound in Elicio Therapeutics Inc.Stable Swing Setup with Safety Analysis - Newser
Is Elicio Therapeutics Inc. Stock a Good Fit for Conservative InvestorsFree Smart Trade Plans With Risk Protection - Newser
How volatile is Elicio Therapeutics Inc. stock compared to the marketStock Strategy Review That Work - jammulinksnews.com
How Elicio Therapeutics Inc. stock performs during market volatilityTrading Volume Spike and Reversal Analysis - Newser
Elicio Therapeutics Inc. Forms Bullish Flag — Upside AheadStep-by-Step Stock Investment Guide Gains Popularity - metal.it
What are Elicio Therapeutics Inc. company’s key revenue driversStock Strategy Picks For 2025 - jammulinksnews.com
Why is Elicio Therapeutics Inc. stock attracting strong analyst attentionChart Pattern Opportunities With High Returns - jammulinksnews.com
Market reaction to Elicio Therapeutics Inc.’s recent newsFree Low Risk Buy Zone Opportunity Watch - Newser
Applying chart zones and confluence areas to Elicio Therapeutics Inc.Free Wealth Building Stock Market Ideas - Newser
Elicio Therapeutics Inc. recovery potential after sell offFree Trade Scanner With Buy Zone Alerts - Newser
How hedge fund analytics apply to Elicio Therapeutics Inc. stockFree Trend Analysis for Safer Trades - Newser
Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - The Globe and Mail
Analyzing recovery setups for Elicio Therapeutics Inc. investorsDaily Pick Forecast with Entry Zones - Newser
Analyzing Elicio Therapeutics Inc. with multi timeframe chartsMulti-Bagger Detection with Trend Tools - Newser
Is Elicio Therapeutics Inc. Stock Overbought or Oversold RSI Indicator AnalysisFree Opportunity Map for Daily Stock Trading - Newser
Developing predictive dashboards with Elicio Therapeutics Inc. dataSummary of Consistent Growth Stock Picks - Newser
Why Elicio Therapeutics Inc. stock attracts strong analyst attentionRisk-Managed Trade Alerts for Consistency - Newser
Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks With ‘Strong Buy’ Ratings - Barchart.com
Published on: 2025-07-28 18:37:53 - metal.it
How strong is Elicio Therapeutics Inc. company’s balance sheetExponential wealth increase - jammulinksnews.com
Trapped Investors in Elicio Therapeutics Inc. Await Breakout SignalInvestment Plan With Growth Optimization Finalized - metal.it
What is the risk reward ratio of investing in Elicio Therapeutics Inc. stockAchieve exceptional returns with expert guidance - jammulinksnews.com
What institutional investors are buying Elicio Therapeutics Inc. stockTrack top-performing stocks in real-time - jammulinksnews.com
What are analysts’ price targets for Elicio Therapeutics Inc. in the next 12 monthsExceptional stock performance - jammulinksnews.com
Is it the right time to buy Elicio Therapeutics Inc. stockUnlock exclusive stock market insights - jammulinksnews.com
How does Elicio Therapeutics Inc. generate profit in a changing economyGame-changing capital returns - jammulinksnews.com
What are the technical indicators suggesting about Elicio Therapeutics Inc.Achieve rapid capital gains with smart investing - jammulinksnews.com
Is Elicio Therapeutics Inc. a growth stock or a value stockExplosive market performance - jammulinksnews.com
Should I hold or sell Elicio Therapeutics Inc. stock in 2025Tremendous return on equity - jammulinksnews.com
Key External Factors That Drive Elicio Therapeutics Inc. Stock Price MovementsRisk Limited High Gain Trades - Newser
Elicio Therapeutics Inc Stock (ELTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):